Posted by Michael Wonder on 25 Mar 2025
GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency
24 March 2025 - Submission based on data from MATINEE trial, which showed a statistically significant and clinically meaningful reduction in the annualised rate of moderate/severe exacerbations with mepolizumab versus placebo.
GSK today announced that the EMA has accepted for review its application to expand the use of Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5, as an add-on maintenance treatment for patients with chronic obstructive pulmonary disease with an eosinophilic phenotype.
